drugset / Trial / NCT03171831
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety and efficacy of haploidentical hematopoietic stem cell transplantation for patients with thalassemia major.
Timeline
- Start
- 2017-04-01
- Primary completion
- 2021-12-31
- Completion
- 2022-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Basiliximab | Monoclonal antibody | 10 mg | — |
| Background | Busulfan | Small molecule | 4 mg/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Background | Fludarabine | Small molecule | 50 mg/m2 | — |
| Background | Methotrexate | Small molecule | 10 mg/m2 | — |
| Background | Mycophenolate Mofetil | Small molecule | 0.25 g | — |
| Background | Tacrolimus | Small molecule | 0.03 mg/kg | — |
| Background | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | — |